Update from ASCO 2023: Late-Breaking RCC Data

Medical Oncologist Prof. Thomas Powles discusses key RCC data from the CONTACT-03, KEYNOTE-426 and CLEAR trials presented at ASCO 2023, and shares his views on the implications for clinical practice.

Watch the short video and download the accompanying slides for your reference.

Clinical Takeaways

• CONTACT-03: For patients with mRCC, adding the atezolizumab to cabozantinib did not improve clinical outcomes compared with treatment with cabozantinib alone and higher toxicities were also observed in the combination arm

• KEYNOTE-426: Pembrolizumab + axitinib continued to demonstrate improved OS, PFS, and ORR versus sunitinib for patients with previously untreated clear cell RCC and no new safety signals were observed

• CLEAR: The combination of lenvatinib plus pembrolizumab remains superior to sunitinib on clinical outcomes as first-line treatment for advanced renal cell carcinoma after 4-years follow-up with no new safety signals detected

• Long-term follow up data from KEYNOTE-426 and the CLEAR trial re-confirms current clinical practice of frontline combination immunotherapy/TKI for IDMC intermediate/poor risk patients